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Objectives: The proportion of tuberculosis (TB) cases occurring in migrants in Europe is increasing.
Extrapulmonary TB poses challenges in diagnosis and treatment and causes serious morbidity and
mortality, yet its extent in migrant populations is unclear. We assessed patterns of extrapulmonary TB in
migrants across the European Union (EU)/European Free Trade Association (EFTA). We investigated the
proportion of extrapulmonary TB cases among migrants versus non-migrants, and variations by specific
site of disease, reporting European region, and migrant region of origin.
Methods: We carried out a cross-sectional secondary database analysis, utilizing 23 years of data
collected between 1995 and 2017 from the European Surveillance System of the European Centre for
Disease Prevention and Control for 32 EU/EFTA countries.
Results: In total, 1 270 896 TB cases were included, comprising 326 987 migrants (25.7%) and 943 909
non-migrants (74.3%). Of TB cases among migrants, 45.2% (n ¼ 147 814) were extrapulmonary compared
to 21.7% (n ¼ 204 613) among non-migrants (p < 0.001). Lymphatic, bone/joint and peritoneal/digestive
TB were more common among migrant than non-migrant extrapulmonary cases. A lower proportion of
extrapulmonary TB was seen in Eastern Europe (17.4%, n ¼ 98 656 of 566 170) and Southern Europe
(29.6%, n ¼ 62 481 of 210 828) compared with Western (35.7%, n ¼ 89 498 of 250 517) and Northern
Europe (41.8%, n ¼ 101 792 of 243 381). Migrants from South-East Asia and Sub-Saharan Africa were at
highest risk of extrapulmonary disease, with 62.0% (n ¼ 55 401 of 89 353) and 54.5% (n ¼ 38 327 of
70 378) of cases, respectively, being extrapulmonary.
Conclusions: Among TB cases in the EU/EFTA, extrapulmonary disease is significantly more common in
migrants than in non-migrants. There is a need to improve clinical awareness of extrapulmonary TB and
to integrate its detection into screening programmes. Sally E. Hayward, Clin Microbiol Infect 2020;▪:1
© 2020 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).Introduction
The proportion of tuberculosis (TB) cases in migrants has been
rising across high-income countries in Europe [1] and the United
States of America (USA) [2]. In 2017, migrants comprised 33.1% of TB
cases across countries of the European Union/European Economic
Area (EU/EEA), and over 70% in parts of Northern and Western
Europe [3]. This trend is set to continue, as TB notification rates arer Infection and Immunity, St
don, SW17 0RE, UK.
d).
Ltd on behalf of European Society
es/by/4.0/).
Extrapulmonary tuberculosi
.12.006falling faster in native-born residents than in those of foreign origin
in the EU/EEA [4]. In addition, migrant populations in high-income
countries are growing, with 4.4 million people migrating to an EU
Member State during 2017 [5].
While TB most commonly affects the lungs, it can present in
almost any organ of the body, including the lymph nodes, pleura,
central nervous system (CNS), bones and joints, genitourinary tract
and gastrointestinal system [6], or disseminated as miliary TB [7].
While not usually transmissible, extrapulmonary TB can cause
serious morbidity and mortality. It is more common among
immunosuppressed individuals such as those with HIV/AIDS.
Extrapulmonary TB poses challenges in diagnosis and treatment
due to its wide variety of non-specific clinical presentations [8].of Clinical Microbiology and Infectious Diseases. This is an open access article under
s among migrants in Europe, 1995 to 2017, Clinical Microbiology and
Fig. 1. Sample flow chart. EU/EFTA, European Union/European Free Trade Association;
TB, tuberculosis.
S.E. Hayward et al. / Clinical Microbiology and Infection xxx (xxxx) xxx2Globally, 15% of the 7 million incident TB cases notified in 2018
were extrapulmonary [9]. Despite this, extrapulmonary TB is rarely
specifically incorporated into TB control programmes, including
those targeting migrants. Current guidance from the European
Centre for Disease Prevention and Control (ECDC) recommends
screening for active pulmonary TB using chest x-ray and screening
for latent tuberculosis infection (LTBI) using the tuberculin skin test
(TST) or an interferon-g release assay (IGRA) soon after migrants
from countries with a high incidence of TB arrive in the EU/EEA
[10], with no specific provision for detecting extrapulmonary
disease.
Patterns of extrapulmonary TB in migrants are not well under-
stood, despite implications for morbidity and mortality. We aim to
assess patterns of extrapulmonary TB in migrants in EU/European
Free Trade Association (EFTA) countries through analysis of the
ECDC's European Surveillance System (TESSy) database. The spe-
cific objectives are to examine whether the proportion of extrap-
ulmonary TB cases is greater in migrants than in non-migrants,
which specific sites of extrapulmonary disease are more or less
common in migrants, and how the distribution of cases varies by
European reporting region and migrants' region of origin.
Methods
Data and definitions
We analysed 23 years of data from ECDC's TESSy database for 32
EU/EFTA countries (henceforth ‘Europe’) collected between its
inception in 1995 and 2017. Detailed data collection methods and
definitions have been described [3]. In brief, designated experts
within national surveillance institutes submit case-based data to
TESSy, where a TB case is defined following the World Health Or-
ganization (WHO) as a bacteriologically confirmed or clinically
diagnosed case [11]. Data on all reported cases in Europe between
1995 and 2017 were extracted.
The analysis was restricted to TB cases with known migrant
status and TB site. We define a migrant as a person born in, or
having citizenship of, a country different from the reporting
country. Extrapulmonary TB is classified as a case involving organs
or anatomical sites other than the lungs, with or without coexistent
lung disease. Specific sites of extrapulmonary TB were grouped as:
lymphatic, pleural, bone/joint (including spine), disseminated,
genitourinary, peritoneal/digestive, CNS (including meningitis),
and other. Region of Europe was defined using the United Nations
Geoscheme for Europe: Eastern, Northern, Southern and Western
[12]. Region of origin was defined using an adaptation of World
Bank regions: Eastern Europe and Central Asia, Europe, North
America and Oceania, Latin America and the Caribbean, Middle East
and North Africa, South-East Asia, and Sub-Saharan Africa [13].
Definitions are presented in the Supplementary Material Fig. S1.
Statistical methods
We assessed how key demographic characteristics differed be-
tween migrants and non-migrants, using t tests for continuous
variables and c2 tests for categorical variables. We compared the
difference in the proportion of extrapulmonary TB between mi-
grants and non-migrants using c2 tests. We repeated this analysis
in subgroups, firstly dividing the sample into drug-susceptible and
multidrug-resistant (MDR) TB (MDR being defined as resistance to
at least isoniazid and rifampicin), and secondly dividing the study
period in two (1995e2006 and 2007e2017). In addition, we used
two-sample tests of proportion to compare the difference in pro-
portion of extrapulmonary TB at a given site between migrants and
non-migrants, c2 tests to compare the proportion of TBs that arePlease cite this article as: Hayward SE et al., Extrapulmonary tuberculosi
Infection, https://doi.org/10.1016/j.cmi.2020.12.006extrapulmonary between the different regions of Europe, and one-
sample tests of proportion to compare the difference in proportion
of pulmonary versus extrapulmonary TB in each migrant region of
origin. In sensitivity analyses, we repeated these analyses defining
extrapulmonary TB as cases involving only organs or anatomical
sites other than the lungs. A value of p < 0.01 was considered sta-
tistically significant. All analyses were conducted using StataSE v15.Ethical statement
The study was based on data collected on the basis of statutory
notification in each EU/EFTA country and reported anonymously to
ECDC per decision No 2119/98/EC of the European Parliament and
of the Council.Results
Sample characteristics
In total,1 611762 TB cases were notified in the EU/EFTA between
1995 and 2017 and reported in TESSy, of which 1 270 896 (78.9%)
had data available on migrant status and TB site and were included
in the analyses (Fig. 1). The included sample comprises 326 987
migrants (25.7%) and 943 909 non-migrants (74.3%). Migrant re-
gions of origin and destination are shown in the Supplementary
Material Fig. S2, and sample characteristics by migrant status are
presented in Table 1.
The mean age of included migrants with TB was 38 years
compared with 48 years in non-migrants (p < 0.001), and 59.9% of
migrants (n¼ 195 264 of 326 208) were male compared with 66.0%
of non-migrants (n ¼ 622 902 of 943 438) (p < 0.001). Migrant TB
cases in the EU/EFTA originate from diverse areas of theworld, most
commonly South-East Asia (34.2%, n ¼ 89 303 of 261 074) and Sub-
Saharan Africa (26.9%, n ¼ 70 341). The most common countries of
origin for migrants with TB are India (n ¼ 30 174), Pakistan
(n ¼ 23 081), Somalia (n ¼ 20 453), and Romania (n ¼ 14 620). In
Eastern and Southern Europe, the majority of TB cases are in non-
migrants, whereas in Northern and Western Europe around half
are in migrants. Migrants were reported to be less likely than non-
migrants to have been previously diagnosed with TB (p < 0.001).Extrapulmonary TB in migrants
The proportion of TB that is extrapulmonary is significantly
greater among migrants than non-migrants (Fig. 2): 45.2% of cases
among migrants (n ¼ 147 814 of 326 987) were extrapulmonary,
compared to 21.7% among non-migrants (n ¼ 204 613 of 943 909)
(p < 0.001). This pattern is seen in both drug-susceptible and MDR
TB (both p < 0.001), and in the earlier (1995e2006) and laters among migrants in Europe, 1995 to 2017, Clinical Microbiology and
Table 1
Characteristics of migrant and non-migrant tuberculosis (TB) cases in the European Union/European Free Trade Association (EU/EFTA), 1995e2017 (n ¼ 1 270 896)
Migrants Non-migrants Total
n % n % n %
Total 326 987 25.7 943 909 74.3 1 270 896
Age:
Mean, SD 37.9 16.8 47.8 20.3 45.3 19.9
Gender:
Female 130 944 40.1 320 536 34.0 451 480 35.6
Male 195 264 59.9 622 902 66.0 818 166 64.4
Region of origin:
Eastern Europe andCentral Asia 56 310 21.6 558 595 63.1 614 905 53.6
Europe, North America and Oceania 24 392 9.3 326 970 36.9 351 362 30.6
Latin America and the Caribbean 11 329 4.3 d 11 330 1.0
Middle East andNorth Africa 9399 3.6 d 9405 0.8
South-East Asia 89 303 34.2 d 89 353 7.8
Sub-Saharan Africa 70 341 26.9 d 70 378 6.1
Reporting region:
Eastern Europe 4921 1.5 561 249 59.5 566 170 44.6
Southern Europe 69 159 21.2 141 669 15.0 210 828 16.6
Western Europe 128 360 39.3 122 157 12.9 250 517 19.7
Northern Europe 124 547 38.1 118 834 12.6 243 381 19.2
Previous TB diagnosis:
Yes 24 864 10.4 143 771 17.0 168 635 15.5
No 213 423 89.6 703 879 83.0 917 302 84.5
Site of TB:
Pulmonary 179 173 54.8 739 296 78.3 918 469 72.3
Extrapulmonarya 147 814 45.2 204 613 21.7 352 427 27.7
Data reported as: n, % unless otherwise stated. Sample sizes: age, n ¼ 1 268 544; gender, n ¼ 1 269 646; region of origin, n ¼ 1 146 733; reporting region, n ¼ 1 270 896;
previous TB diagnosis, n¼ 1 085 937; site of TB, n¼ 1 270 896. The difference betweenmigrants and non-migrants for each characteristic is statistically significant at p < 0.001
calculated using t test for continuous variables or c2 for categorical variables: age, t ¼ 251.9; gender, c2 ¼ 4.0  103; reporting region, c2 ¼ 3.6  105; previous TB diagnosis,
c2 ¼ 6.0  103; site of TB, c2 ¼ 6.7  104.
a Extrapulmonary TB defined as any case of TB involving organs or anatomical sites other than the lungs, with or without co-existent lung disease.
Fig. 2. Site of tuberculosis (TB) among migrant and non-migrant TB cases in the Eu-
ropean Union/European Free Trade Association (EU/EFTA), 1995e2017 (n ¼ 1 270 896).
Extrapulmonary TB is defined as any case of TB involving organs or anatomical sites
other than the lungs, with or without coexistent lung disease. p value calculated using
c2 test (c2 ¼ 6.7  104, p < 0.001).
S.E. Hayward et al. / Clinical Microbiology and Infection xxx (xxxx) xxx 3(2007e2017) parts of the study period (both p < 0.001)
(Supplementary Material Table S1).
Among extrapulmonary TB cases, specific site varies by migrant
status (Table 2). For migrants, 47.6% of extrapulmonary TB is
lymphatic (n ¼ 37 150 of 78 077), compared with 25.3% in non-
migrants (n ¼ 43 933 of 173 604) (p < 0.001). This varies by
country of origin; for example, amongmigrants from India, 52.4% of
extrapulmonary TB is lymphatic (n ¼ 2079 of 3971). Conversely,
17.6% of extrapulmonary TB is pleural in migrants (n ¼ 13 730 ofPlease cite this article as: Hayward SE et al., Extrapulmonary tuberculosi
Infection, https://doi.org/10.1016/j.cmi.2020.12.00678 077) versus 42.1% in non-migrants (n ¼ 73 052 of 173 604)
(p < 0.001); 24 965 TB cases (4336 migrants and 20 629 non-
migrants) were reported to include both pulmonary and pleural
involvement. Differences are also seen for bone/joint TB (p < 0.001)
and peritoneal/digestive TB (p < 0.001), which are relatively more
common in migrants than in non-migrants, and for genitourinary
TB (p < 0.001), which is less common in migrants.
Extrapulmonary TB by European reporting region
A relatively low proportion of extrapulmonary TB is seen in
Eastern Europe (17.4%, n ¼ 98 656 of 566 170) and Southern Europe
(29.6%, n ¼ 62 481 of 210 828) compared with Western Europe
(35.7%, n ¼ 89 498 of 250 517) and Northern Europe (41.8%,
n ¼ 101 792 of 243 381) (Table 3). Migrants are reported to have a
greater proportion of extrapulmonary TB than non-migrants only
in Western and Northern Europe (both p < 0.001). For example, in
Northern Europe, 58.5% of TB (n ¼ 72 868 of 124 547) is extrap-
ulmonary among migrant cases compared with 24.3% (n ¼ 28 924
of 118 834) among non-migrants (p < 0.001). Fig. 3 shows that in
Northern and Western European countries a high proportion of TB
occurs in migrants, with a particularly high proportion of extrap-
ulmonary TB occurring among migrants. In Southern and Eastern
European countries, a lower proportion of TB is in migrants, and
this pattern does not differ markedly between pulmonary and
extrapulmonary TB.
Extrapulmonary TB and migrants' region of origin
Over half of TB cases are extrapulmonary among migrants from
South-East Asia (62.0%, n ¼ 55 401 of 89 353, p < 0.001) and Sub-
Saharan Africa (54.5%, n ¼ 38 327 of 70 378, p < 0.001) (Fig. 4),
which are the most common regions of origin for migrant TB cases
in Europe. For example, of 30 174 TB cases among migrants froms among migrants in Europe, 1995 to 2017, Clinical Microbiology and
Table 3
Site of tuberculosis (TB) among cases reported by countries in the Eastern, Southern,
Western and Northern regions of the European Union/European Free Trade Asso-
ciation (EU/EFTA), 1995e2017 (n ¼ 1 270 896)
Pulmonary TB Extrapulmonary TBa Total
n % n % n
Eastern Europe: 467 514 82.6 98 656 17.4* 566 170
Migrant 3994 81.2 927 18.8 4921
Non-migrant 463 520 82.6 97 729 17.4 561 249
Southern Europe: 148 347 70.4 62 481 29.6* 210 828
Migrant 47 908 69.3 21 251 30.7 69 159
Non-migrant 100 439 70.9 41 230 29.1 141 669
Western Europe: 161 019 64.3 89 498 35.7* 250 517
Migrant 75 592 58.9 52 768 41.1 128 360
Non-migrant 85 427 69.9 36 730 30.1 122 157
Northern Europe: 141 589 58.2 101 792 41.8* 243 381
Migrant 51 679 41.5 72 868 58.5 124 547
Non-migrant 89 910 75.7 28 924 24.3 118 834
Total 918 469 72.3 352 427 27.7 1 270 896
* The difference in proportion of TB that is extrapulmonary between each region and
each other region is significant at p < 0.001, p values calculated using c2 (e.g. Eastern
versus Northern Europe c2 ¼ 5.4  104, p < 0.001).
a Extrapulmonary TB is defined as any case of TB involving organs or anatomical
sites other than the lungs, with or without co-existent lung disease.
Table 2
Site of tuberculosis (TB) among migrant and non-migrant extrapulmonary TBa cases
in the European Union/European Free Trade Association (EU/EFTA), 1995e2017
(n ¼ 251 681)
Migrants Non-migrants
n % n %
Lymphatic 37 150 47.6* 43 933 25.3
Pleural 13 730 17.6y 73 052 42.1
Bone/joint incl. spine 6417 8.2* 12 513 7.2
Disseminated 3947 5.1* 8245 4.8
Genitourinary 3174 4.1y 11 547 6.7
Peritoneal/digestive 3091 4.0* 3879 2.2
CNS incl. meningitis 2775 3.6* 5835 3.4
Otherb 7793 10.0* 14 600 8.4
Totalc 78 077 173 604
CNS, central nervous system.
*Proportion is higher in migrants.
yProportion is higher in non-migrants.
a Extrapulmonary TB is defined as any case of TB involving organs or anatomical
sites other than the lungs, with or without coexistent lung disease.
b ‘Other’ refers to TB infection in any organ or anatomical site of the body that falls
outside the specified categories.
c There are an additional 100 746 cases not reported here for which the site of TB
is known to be extrapulmonary, but the exact site is unknown.
S.E. Hayward et al. / Clinical Microbiology and Infection xxx (xxxx) xxx4India, 21 303 (70.6%) were extrapulmonary. In contrast, the pro-
portion of reported extrapulmonary disease is particularly low
among migrants from Eastern Europe and Central Asia (20.6%,
n ¼ 11 576 of 56 310, p < 0.001).
Sensitivity analyses
In sensitivity analyses, we established that these patterns are
seenwhether extrapulmonary TB is defined as any extrapulmonary
or only extrapulmonary TB (Supplementary Material Figs S3, S4 and
Tables S2eS4).
Discussion
We found that the proportion of TB that is extrapulmonary
is significantly greater among migrants than non-migrants.Please cite this article as: Hayward SE et al., Extrapulmonary tuberculosi
Infection, https://doi.org/10.1016/j.cmi.2020.12.006These data are consistent with single-country studies in the
UK and the Netherlands indicating that migrants are at
increased risk of extrapulmonary TB [14,15]. The reasons for
this are not fully understood. At a time of rising migration to
Europe and other high-income countries, with a growing pro-
portion of TB cases occurring in migrants [2,5], extrapulmonary
TB in this group is an increasingly important issue. Indeed, the
reported proportion of extrapulmonary TB increased from
16.4% in 2002 to 22.4% in 2011 in the EU/EEA [16]. Extrap-
ulmonary TB poses challenges in diagnosis and treatment, with
implications for patient outcomes. Thus, migrants' dispropor-
tionate burden of extrapulmonary TB may contribute to their
worse treatment outcomes [17].
We found that specific site of extrapulmonary TB varies by
migrant status. The reasons for this are unclear, but it may reflect
the distribution of types of extrapulmonary TB in the countries of
origin. For example, India has relatively high rates of lymphatic TB
[18], a pattern mirrored among Indian migrants. Migrants were
observed to have a lower proportion of pleural TB than non-
migrants. However, this should be interpreted with caution, as
many cases were reported to include both pulmonary and pleural
involvement. Such cases may be classified as having pulmonary
plus pleural disease (i.e. extrapulmonary), or as pulmonary disease
only. Differences are also seen for other sites of TB (bone/joint,
peritoneal/digestive, and genitourinary). However, the absolute
numbers of cases are low for these extrapulmonary sites, so a sta-
tistical difference may have relatively small clinical implications.
These could also potentially be artefacts; for example, genitouri-
nary TB may be misdiagnosed as more common sexually trans-
mitted infections or urinary tract infections, delaying the diagnosis
of TB [19].
We also found a higher proportion of extrapulmonary TB in
Northern and Western Europe compared with Southern and
especially Eastern Europe, with the disproportionate burden of
extrapulmonary TB among migrants seen only in Northern and
Western Europe. The reasons for this are unclear. Extrapulmonary
TB is thought usually to follow reactivation of latent infection rather
than occurring at initial infection, with the exception of TB men-
ingitis [20]. Most migrant TB cases are infected before they arrive in
host countries, with subsequent reactivation of LTBI [21]. This is
especially true in final-destination, high-income countries of
Northern and Western Europe, which may contribute to the higher
prevalence of extrapulmonary TB in migrants in these regions.
Transit countries in Southern and Eastern Europe may see a slightly
higher proportion of migrants arriving with active TB or trans-
mission, for example in refugee camps [22]. In addition, healthcare
access for migrants varies significantly across Europe [23], and once
migrants settle in final-destination countries, they may become
better integrated into health systems and more likely to seek care
for symptoms of extrapulmonary TB. By contrast, public health
initiatives targeting migrants in transit countries tend to focus on
preventing the spread of pulmonary TB. However, even in final-
destination countries migrants often face significant barriers to
healthcare access [24]; therefore, this is unlikely to fully account for
the observed differences across Europe.
The proportion of extrapulmonary TB is highest amongmigrants
from South-East Asia and Sub-Saharan Africa. This is consistent
with data from Germany and across the EU/EEA showing that
migrant TB cases from Asia and Africa were more likely than non-
migrant patients to present with extrapulmonary disease [25,26].
Migrants from certain regions may be genetically predisposed to
extrapulmonary manifestations of TB [14]. Some countries in
Northern andWestern Europe host large migrant populations from
the Indian subcontinent, where extrapulmonary TB is relatively
common [18]. Extrapulmonary TB is also more common in thes among migrants in Europe, 1995 to 2017, Clinical Microbiology and
Fig. 3. Proportion of pulmonary and extrapulmonary tuberculosis (TB) among migrant and non-migrant TB cases in selected countries of the European Union/European Free Trade
Association (EU/EFTA), 1995e2017. Extrapulmonary TB is defined as any case of TB involving organs or anatomical sites other than the lungs, with or without coexistent lung disease.
The boxes in the figure illustrate the proportion of pulmonary and extrapulmonary TB cases that occur in migrants in each country. On the map, the different shadings of the
countries represent the proportions of individuals with foreign citizenship living in that country on 1st January 2016 (source: Eurostat, online data code: migr_pop1ctz).
S.E. Hayward et al. / Clinical Microbiology and Infection xxx (xxxx) xxx 5immunosuppressed, including HIV/AIDS patients [27], and the high
burden of TBeHIV co-morbidity in Sub-Saharan Africa may
contribute to increased risk of extrapulmonary TB [28]. However,
TBeHIV co-morbidity accounts for a small proportion of TB cases in
Europe, and is therefore unlikely to be a major driver of the
observed patterns.
Strengths and limitations
By using surveillance data reported by EU/EFTA Member States
to ECDC between 1995 and 2017, this study utilizes data from over 1
million TB cases, enabling a comprehensive analysis of patterns of
extrapulmonary TB in migrants across Europe. In all EU/EFTA
countries, TB is a notifiable disease; however, data quality varies
significantly between national surveillance systems, and there are
gaps in reporting. We excluded 340 866 TB cases from our analyses
because they lacked data on either migrant status or site of TB. The
proportion of all notified TB cases that have these data available,Please cite this article as: Hayward SE et al., Extrapulmonary tuberculosi
Infection, https://doi.org/10.1016/j.cmi.2020.12.006and are therefore included, increases over time, from below 50% up
to 2001 to over 80% from 2002 and over 90% since 2004
(Supplementary Material Table S5).
Most covariates have good completeness in our dataset
(Supplementary Material Table S6). Data on age, gender, and
reporting country are over 99% complete, country of origin is 90%
complete, previous TB diagnosis is ~85% complete, and site of TB
among extrapulmonary cases is ~70% complete. However, HIV
status was collected only from 2000 onwards, meaning that in our
sample only 17% of cases had data on HIV status. This potentially
important variable was therefore excluded from our analyses. The
limited nature of the data available prevented us from unpicking
the relative impact of host and environmental factors and Myco-
bacterium tuberculosis lineage. This warrants further investigation,
as does the pattern of drug resistance in relation tomigration status
and site of TB. Furthermore, migrant status is defined by country of
birth in some countries and country of citizenship in others, which
may influence the findings.s among migrants in Europe, 1995 to 2017, Clinical Microbiology and
Fig. 4. Site of tuberculosis (TB) among migrant TB cases in the European Union/European Free Trade Association (EU/EFTA) by region of origin, 1995e2017 (n ¼ 261 074).
Extrapulmonary TB is defined as any case of TB involving organs or anatomical sites other than the lungs, with or without coexistent lung disease. *p < 0.001, a greater proportion of
TB is pulmonary. yp <0.001, a greater proportion of TB is extrapulmonary. p values are two-sided, calculated using one-sample test of proportion (H0 ¼ the proportions of pulmonary
and extrapulmonary TB are equal).
S.E. Hayward et al. / Clinical Microbiology and Infection xxx (xxxx) xxx6Implications
The findings have important clinical implications for migrant-
receiving countries, particularly in Northern and Western Europe.
Although there are many reports and guidelines relating to man-
aging TB and migrant health, none adequately addresses the key
issues arising from extrapulmonary TB in this group. There is a need
to improve diagnostic facilities and awareness of extrapulmonary
TB among healthcare staff, particularly when assessing patients
from South-East Asia and Sub-Saharan Africa. In addition, detection
of extrapulmonary TB should be integrated into screening pro-
grammes, with a focus on migrants. Extrapulmonary TB must be
considered when screening for latent as well as active disease,
when it is essential to ascertain that patients do not have active
extrapulmonary disease before initiating preventative chemopro-
phylaxis for LTBI. Programmes that target migrants for LTBI
screening and treatment could therefore have the indirect benefit
of detecting and preventing extrapulmonary TB.Author contributions
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